Anthrax
What is Anthrax?
Bacillus anthracis is a large, gram-positive, spore-forming
bacillus that is found worldwide. The spores are very resistant to heat and drying and may
survive for decades in certain soil conditions. Domestic and wild animals become infected
when they ingest spores while grazing on contaminated land or eat contaminated feed.
Humans become infected by ingesting contaminated meat or through agricultural or
industrial exposure to include contaminated carcasses, hides, wool, hair, and bones. With
the use of vaccine in at-risk workers, as well as a vaccine for animals, there has only
been approximately 1 case of anthrax reported per year for the last 10 years in the U.S.
Most human cases today occur in Africa and Asia where use of the vaccine is not as
widespread.
Progression of Disease
To produce disease, the anthrax spore must be ingested, inhaled, or enter the body
through a break in the skin. Macrophages ingest the spores at the site of entry,
whereupon, the spores germinate into bacteria that rapidly replicate and release toxins.
Inhaled spores are carried to tracheobronchial lymph nodes, where they are ingested and
germinate. Toxins elaborated by multiplying B. anthracis cause edema,
hemorrhage, and local tissue necrosis. Bacteremia and septicemia result and other organs
are usually seeded, including the meninges. In inhalation anthrax, death results from a
combination of respiratory failure with pulmonary edema, overwhelming bacteremia, and
often, meningitis.
Diagnosis of Infection
There are three forms of anthrax: cutaneous anthrax (which accounts for 95
percent of cases of anthrax occurring naturally in the world); gastrointestinal;
and inhalation anthrax. Inhalation anthrax develops following an incubation period
of 1-6 days. The initial symptoms are nonspecific and include malaise, fatigue, myalgia
and fever, as well as a nonproductive cough and mild chest pain. These symptoms usually
persist for 2-3 days, and may even be followed by a short period of improvement. The
terminal symptoms appear suddenly and include increasing respiratory distress with
difficulty breathing, stridor, cyanosis, increased chest pain, and diaphoresis. The most
critical aspect of making the diagnosis of inhalation anthrax is having a high index of
suspicion, since the early symptoms are entirely nonspecific. The clinical picture of
respiratory distress is helpful, especially in association with CXR evidence of a widened
mediastinum, a result of the edema and hemorrhage occurring in the tracheobronchial lymph
nodes. Sputum stains and cultures are not helpful in diagnosis since this is a mediastinal
disease and not a pneumonia. Blood cultures are positive late in the course of the
illness.
Treatment Recommendations
Antibiotic treatment and intensive care must be started at the earliest sign of
disease. Historically, penicillin was the treatment of choice for anthrax. However, in the
absence of information concerning antibiotic sensitivity, the current recommended
treatment is ciprofloxacin 400 mg IV every 8-12 hours or doxycycline 200 mg IV followed by
100 mg IV every 12 hours, along with supportive treatment in an intensive care
environment. Antibiotics are also used as post-exposure treatment within 24 hours
and before onset of symptoms to protect asymptomatic persons after exposure to aerosolized
anthrax spores. If an anthrax exposure is detected, and confirmed, oral antibiotic
treatment should be initiated immediately using ciprofloxacin500 mg orally twice a day,
or doxycycline100 mg orally twice a day for at least 30 days. These exposed, asymptomatic
individuals must also receive at least the first 3 doses of anthrax vaccine.
Reference
-
SECNAVINST 6230.4 Department of the Navy (DON) Anthrax Vaccination Implementation
Program (AVIP)
Written by LCDR Ann Fallon, MC, USN, Headquarters USMC, Arlington Annex,
Arlington, VA (1999).
|
Preface
· Administrative Section
· Clinical Section
The
General Medical Officer Manual , NAVMEDPUB 5134, January 1, 2000
Bureau
of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C.,
20372-5300
This
web version of The General Medical Officer Manual, NAVMEDPUB 5134 is provided by
The Brookside Associates
Medical Education Division. It contains original contents from the
official US Navy version, but has been reformatted for web access and
includes advertising and links that were not present in the original version.
This web version has not been approved by the Department of the Navy or the
Department of Defense. The presence of any advertising on these pages does not
constitute an endorsement of that product or service by either the Department of
Defense or the Brookside Associates. The Brookside Associates is a private
organization, not affiliated with the United States Department of Defense. All
material in this version is unclassified. This formatting © 2006
Medical Education Division,
Brookside Associates, Ltd.
All rights reserved.
Home
·
Textbooks and Manuals
·
Videos
·
Lectures
·
Distance Learning
·
Training
·
Operational Safety
·
Search
This website is dedicated to the development and dissemination of medical information that may be useful to those who practice Operational Medicine. This website is privately-held and not connected to any governmental agency. The views expressed here are those of the authors, and unless otherwise noted, do not necessarily reflect the views of
the Brookside Associates, Ltd., any governmental or private organizations. All writings, discussions, and publications on this website are unclassified.
© 2006 Medical Education Division, Brookside Associates, Ltd. All rights reserved
Other Brookside Products
Contact Us
|
|